There was no uniform and simple trend linking the changes in physiology/biology in Crohn’s disease patients to changes in drug bioavailability and disposition.

Inadequate clinical and proteomics data were identified as hurdles to incorporate relevant information into physiologically based pharmacokinetic models for creation of reliable predictive virtual populations of Crohn’s disease patients. Initial assessment of the models identified the major physiological influencers and the knowledge gaps for prudent prediction of altered pharmacokinetics in Crohn’s disease.